Literature DB >> 9593169

Antibacterial activities and inhibitory effects of sitafloxacin (DU-6859a) and its optical isomers against type II topoisomerases.

T Akasaka1, S Kurosaka, Y Uchida, M Tanaka, K Sato, I Hayakawa.   

Abstract

The in vitro inhibitory effects of sitafloxacin (DU-6859a) and its three stereoisomers on bacterial DNA gyrase from Escherichia coli, topoisomerase IV from Staphylococcus aureus, and topoisomerase II from human placenta were compared. No correlation was observed between the inhibitory activities of quinolones against bacterial type II topoisomerases and those against human topoisomerase II. Sitafloxacin showed the most potent inhibitory activities against bacterial type II topoisomerases and the lowest activity against human type II topoisomerase.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9593169      PMCID： PMC105807          DOI： 10.1128/AAC.42.5.1284

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  30 in total

1.  Significance of the methyl group on the oxazine ring of ofloxacin derivatives in the inhibition of bacterial and mammalian type II topoisomerases.

Authors:  K Hoshino; K Sato; K Akahane; A Yoshida; I Hayakawa; M Sato; T Une; Y Osada
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

2.  DNA gyrase: an enzyme that introduces superhelical turns into DNA.

Authors:  M Gellert; K Mizuuchi; M H O'Dea; H A Nash
Journal:  Proc Natl Acad Sci U S A       Date:  1976-11       Impact factor: 11.205

3.  New topoisomerase essential for chromosome segregation in E. coli.

Authors:  J Kato; Y Nishimura; R Imamura; H Niki; S Hiraga; H Suzuki
Journal:  Cell       Date:  1990-10-19       Impact factor: 41.582

4.  Mechanism of inhibition of DNA gyrase by quinolone antibacterials: a cooperative drug--DNA binding model.

Authors:  L L Shen; L A Mitscher; P N Sharma; T J O'Donnell; D W Chu; C S Cooper; T Rosen; A G Pernet
Journal:  Biochemistry       Date:  1989-05-02       Impact factor: 3.162

5.  Inhibitory effects of quinolones on DNA gyrase of Escherichia coli and topoisomerase II of fetal calf thymus.

Authors:  K Hoshino; K Sato; T Une; Y Osada
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

6.  Mechanism of quinolone inhibition of DNA gyrase. Appearance of unique norfloxacin binding sites in enzyme-DNA complexes.

Authors:  L L Shen; W E Kohlbrenner; D Weigl; J Baranowski
Journal:  J Biol Chem       Date:  1989-02-15       Impact factor: 5.157

7.  Inhibitory activities of quinolones against DNA gyrase and topoisomerase IV purified from Staphylococcus aureus.

Authors:  M Tanaka; Y Onodera; Y Uchida; K Sato; I Hayakawa
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

Review 8.  Biology of bacterial deoxyribonucleic acid topoisomerases.

Authors:  K Drlica
Journal:  Microbiol Rev       Date:  1984-12

9.  Tandem regions of yeast DNA topoisomerase II share homology with different subunits of bacterial gyrase.

Authors:  R Lynn; G Giaever; S L Swanberg; J C Wang
Journal:  Science       Date:  1986-08-08       Impact factor: 47.728

10.  Mechanism of inhibition of DNA gyrase by quinolone antibacterials: specificity and cooperativity of drug binding to DNA.

Authors:  L L Shen; J Baranowski; A G Pernet
Journal:  Biochemistry       Date:  1989-05-02       Impact factor: 3.162
View more
  7 in total

1.  Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997-1998 respiratory season.

Authors:  M E Jones; D F Sahm; N Martin; S Scheuring; P Heisig; C Thornsberry; K Köhrer; F J Schmitz
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

2.  Contributions of the 8-methoxy group of gatifloxacin to resistance selectivity, target preference, and antibacterial activity against Streptococcus pneumoniae.

Authors:  H Fukuda; R Kishii; M Takei; M Hosaka
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

3.  Molecular characteristics and in vitro susceptibility to antimicrobial agents, including the des-fluoro(6) quinolone DX-619, of Panton-Valentine leucocidin-positive methicillin-resistant Staphylococcus aureus isolates from the community and hospitals.

Authors:  Tatsuo Yamamoto; Soshi Dohmae; Kohei Saito; Taketo Otsuka; Tomomi Takano; Megumi Chiba; Katsuko Fujikawa; Mayumi Tanaka
Journal:  Antimicrob Agents Chemother       Date:  2006-10-16       Impact factor: 5.191

4.  Cloning, expression, and enzymatic characterization of Pseudomonas aeruginosa topoisomerase IV.

Authors:  T Akasaka; Y Onodera; M Tanaka; K Sato
Journal:  Antimicrob Agents Chemother       Date:  1999-03       Impact factor: 5.191

5.  Sitafloxacin activity against Helicobacter pylori isolates, including those with gyrA mutations.

Authors:  Kazunari Murakami; Tadayoshi Okimoto; Masaaki Kodama; Jin Tanahashi; Toshio Fujioka; Fumiaki Ikeda; Hiroe Muraoka; Motoko Takigawa; Takeshi Saika; Miyuki Hasegawa; Intetsu Kobayashi
Journal:  Antimicrob Agents Chemother       Date:  2009-04-20       Impact factor: 5.191

6.  Alternative eradication regimens for Helicobacter pylori infection in Indonesian regions with high metronidazole and levofloxacin resistance.

Authors:  Muhammad Miftahussurur; Langgeng Agung Waskito; Ari Fahrial Syam; Iswan Abbas Nusi; Gontar Siregar; Marselino Richardo; Achmad Fuad Bakry; Yudith Annisa Ayu Rezkitha; I Dewa Nyoman Wibawa; Yoshio Yamaoka
Journal:  Infect Drug Resist       Date:  2019-01-31       Impact factor: 4.003

7.  A High-Throughput Screening Approach To Repurpose FDA-Approved Drugs for Bactericidal Applications against Staphylococcus aureus Small-Colony Variants.

Authors:  Ryan P Trombetta; Paul M Dunman; Edward M Schwarz; Stephen L Kates; Hani A Awad
Journal:  mSphere       Date:  2018-10-31       Impact factor: 4.389
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.